GLSI Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers...

Stats
Dagens volum	27 889.00
Gjennomsnittsvolum	52 203.00
Markedsverdi	168.96M
EPS	$0 ( 2024-03-29 )
Neste inntjeningsdato	( $-0.200 ) 2024-05-27
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-19.01
ATR14	$0.170 (1.31%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Patel Snehal	Buy	3 000	Common Stock
2024-03-22	Patel Snehal	Buy	2 500	Common Stock
2024-03-20	Patel Snehal	Buy	1 500	Common Stock
2024-03-05	Patel Snehal	Buy	30 500	Common Stock
2024-03-04	Patel Snehal	Buy	4 100	Common Stock

INSIDER POWER
100.00
Last 96 transactions
Buy: 968 139 \| Sell: 271 338

Volum Korrelasjon

Lang: -0.13 (neutral)

Kort: 0.94 (very strong)

Signal:(56.048) Expect same movement, but be aware

Greenwich LifeSciences, Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Greenwich LifeSciences, Korrelasjon - Valuta/Råvare

0.06
( neutral )

0.13
( neutral )

0.00
( neutral )

0.11
( neutral )

-0.16
( neutral )

0.46
( neutral )

Greenwich LifeSciences, Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-3 612.00 (0.00 %)
EPS:	$-0.690

FY	2023
Omsetning:	$0
Bruttogevinst:	$-3 612.00 (0.00 %)
EPS:	$-0.690

FY	2022
Omsetning:	$0
Bruttogevinst:	$-3 612.00 (0.00 %)
EPS:	$-0.590

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.520

Financial Reports:

No articles found.

Greenwich LifeSciences,

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.